Division of Immune Diversity, Department of Immunology and Cancer, German Cancer Research Centre (DKFZ), 69120, Heidelberg, Germany.
Faculty of Biosciences, Heidelberg University, 69120, Heidelberg, Germany.
Nat Commun. 2022 Jun 8;13(1):3308. doi: 10.1038/s41467-022-30862-y.
During the ongoing COVID-19 pandemic, PCR testing and antigen tests have proven critical for helping to stem the spread of its causative agent, SARS-CoV-2. However, these methods suffer from either general applicability and/or sensitivity. Moreover, the emergence of variant strains creates the need for flexibility to correctly and efficiently diagnose the presence of substrains. To address these needs we developed the diagnostic test ADESSO (Accurate Detection of Evolving SARS-CoV-2 through SHERLOCK (Specific High Sensitivity Enzymatic Reporter UnLOCKing) Optimization) which employs Cas13 to diagnose patients in 1 h without sophisticated equipment. Using an extensive panel of clinical samples, we demonstrate that ADESSO correctly identifies infected individuals at a sensitivity and specificity comparable to RT-qPCR on extracted RNA and higher than antigen tests for unextracted samples. Altogether, ADESSO is a fast, sensitive and cheap method that can be applied in a point of care setting to diagnose COVID-19 and can be quickly adjusted to detect new variants.
在持续的 COVID-19 大流行期间,PCR 检测和抗原检测已被证明对帮助阻止其病原体 SARS-CoV-2 的传播至关重要。然而,这些方法要么适用性普遍,要么敏感性不足。此外,变异株的出现需要灵活性来正确、有效地诊断亚株的存在。为了满足这些需求,我们开发了诊断测试 ADESSO(通过 SHERLOCK(特异性高灵敏度酶报告解锁)优化准确检测不断进化的 SARS-CoV-2),该测试使用 Cas13 在 1 小时内无需复杂设备即可诊断患者。使用广泛的临床样本面板,我们证明 ADESSO 能够以与提取 RNA 的 RT-qPCR 相当或高于未提取样本的抗原检测的灵敏度和特异性正确识别感染个体。总的来说,ADESSO 是一种快速、敏感和廉价的方法,可以在护理点应用于诊断 COVID-19,并可以快速调整以检测新的变体。